HRH3 and hereditary elliptocytosis: Taking into consideration subtle changes in histamine‐plasticity and gene expression in the histaminergic system of hyperammonemic mice and in the end‐stage of human HE as well as unimpaired H3R signaling, H3R antagonists/inverse agonists can be suggested as possible vigilance‐increasing therapeutics.